Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETAIN-3: Risk-Enabled Therapy After Neoadjuvant Enfortumab Vedotin/Pembrolizumab for Bladder Cancer
NCT07908979Phase 2Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in bladder carcinoma, sponsored by Fox Chase Cancer Center. Started Oct 2026; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT07908979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908979.